Press Release October 28, 2020

Insitro Announces Up To $2.1 Billion Five-Year Discovery Collaboration With Bristol Myers Squibb To Discover And Develop Novel Treatments For Amyotrophic Lateral Sclerosis And Frontotemporal Dementia

The Life Sciences team advised insitro on its five-year, discovery collaboration with Bristol Myers Squibb (NYSE: BMY) focused on the discovery and development of novel therapies for the treatment of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).

insitro is a machine-learning driven drug discovery and development company. In this collaboration, insitro will apply its proprietary platform, the insitro Human (ISH) platform, to create induced pluripotent stem cell (iPSC) derived disease models for ALS and FTD.

insitro will receive $50 million in an upfront payment and will be eligible to receive an additional $20 million in near term operational milestones and up to an aggregate of more than $2 billion in discovery, development, regulatory and commercial milestones in addition to royalty payments on net product sales.

The Goodwin team was led by Noelle Dubiansky and Kingsley Taft.

For more details, read the press release and articles in Endpoints, Fierce Biotech, and Seeking Alpha.